PMLiVE6h
PMEA 2024: a celebration of excellence in pharmaceutical marketing
PMEA returned on 21 November at the Sheraton Grand in London to recognise excellence within pharmaceutical marketing. The ...
PMLiVE6h
Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients
Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...
PMLiVE2d
Bringing more effective storytelling to medical publications
Traditionally, stories include several key elements: characters, setting, plot and an inciting incident to catalyse the rest of the story through climax and resolution. Stories also have causality – ...
PMLiVE3d
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults
UCB’s Bimzelx (bimekizumab-bkzx) has been approved by the US Food and Drug Administration (FDA) to treat active moderate-to-severe hidradenitis suppurativa (HS) in adults. Estimated to affect one in ...